Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study.
Options
BORIS DOI
Date of Publication
July 2024
Publication Type
Article
Division/Institute
Contributor
Bozonnat, Alizée | |
Beylot-Barry, Marie | |
Dereure, Olivier | |
D'Incan, Michel | |
Quereux, Gaëlle | |
Guenova, Emmanuella | |
Perier-Muzet, Marie | |
Dalle, Stephane | |
Grange, Florent | |
Viguier, Manuelle-Anne | |
Ram-Wolff, Caroline | |
Bonnet, Nathalie | |
Amatore, Florent | |
Maubec, Eve | |
Franck, Nathalie | |
Machet, Laurent | |
Chasset, François | |
Brunet-Possenti, Florence | |
Bouaziz, Jean-David | |
Battistella, Maxime | |
Donzel, Marie | |
Pham-Ledard, Anne | |
Bejar, Claudia | |
Moins-Teisserenc, Hélène | |
Mourah, Samia | |
Saiag, Philippe | |
Hainaut, Ewa | |
Michel, Catherine | |
Bens, Guido | |
Adamski, Henri | |
Aubin, François | |
Boulinguez, Serge | |
Joly, Pascal | |
Tedbirt, Billal | |
Templier, Isabelle | |
Troin, Laura | |
Montaudié, Henri | |
Ingen-Housz-Oro, Saskia | |
Faiz, Sarah | |
Mortier, Laurent | |
Dobos, Gabor | |
Bagot, Martine | |
Resche-Rigon, Matthieu | |
Montlahuc, Claire | |
Serret-Larmande, Arnaud | |
de Masson, Adèle |
Subject(s)
Series
EClinicalMedicine
ISSN or ISBN (if monograph)
2589-5370
Publisher
Elsevier
Language
English
Publisher DOI
PubMed ID
39007062
Uncontrolled Keywords
Description
BACKGROUND
Sézary syndrome is an extremely rare and fatal cutaneous T-cell lymphoma (CTCL). Mogamulizumab, an anti-CCR4 monoclonal antibody, has recently been associated with increased progression-free survival in a randomized clinical trial in CTCL. We aimed to evaluate OS and prognostic factors in Sézary syndrome, including treatment with mogamulizumab, in a real-life setting.
METHODS
Data from patients with Sézary (ISCL/EORTC stage IV) and pre-Sézary (stage IIIB) syndrome diagnosed from 2000 to 2020 were obtained from 24 centers in Europe. Age, disease stage, plasma lactate dehydrogenases levels, blood eosinophilia at diagnosis, large-cell transformation and treatment received were analyzed in a multivariable Cox proportional hazard ratio model. This study has been registered in ClinicalTrials (SURPASSe01 study: NCT05206045).
FINDINGS
Three hundred and thirty-nine patients were included (58% men, median age at diagnosis of 70 years, Q1-Q3, 61-79): 33 pre-Sézary (9.7% of 339), 296 Sézary syndrome (87.3%), of whom 10 (2.9%) had large-cell transformation. One hundred and ten patients received mogamulizumab. Median follow-up was 58 months (95% confidence interval [CI], 53-68). OS was 46.5% (95% CI, 40.6%-53.3%) at 5 years. Multivariable analysis showed that age ≥ 80 versus <50 (HR: 4.9, 95% CI, 2.1-11.2, p = 0.001), and large-cell transformation (HR: 2.8, 95% CI, 1.6-5.1, p = 0.001) were independent and significant factors associated with reduced OS. Mogamulizumab treatment was significantly associated with decreased mortality (HR: 0.34, 95% CI, 0.15-0.80, p = 0.013).
INTERPRETATION
Treatment with mogamulizumab was significantly and independently associated with decreased mortality in Sézary syndrome.
FUNDING
French Society of Dermatology, Swiss National Science Foundation (IZLIZ3_200253/1) and SKINTEGRITY.CH collaborative research program.
Sézary syndrome is an extremely rare and fatal cutaneous T-cell lymphoma (CTCL). Mogamulizumab, an anti-CCR4 monoclonal antibody, has recently been associated with increased progression-free survival in a randomized clinical trial in CTCL. We aimed to evaluate OS and prognostic factors in Sézary syndrome, including treatment with mogamulizumab, in a real-life setting.
METHODS
Data from patients with Sézary (ISCL/EORTC stage IV) and pre-Sézary (stage IIIB) syndrome diagnosed from 2000 to 2020 were obtained from 24 centers in Europe. Age, disease stage, plasma lactate dehydrogenases levels, blood eosinophilia at diagnosis, large-cell transformation and treatment received were analyzed in a multivariable Cox proportional hazard ratio model. This study has been registered in ClinicalTrials (SURPASSe01 study: NCT05206045).
FINDINGS
Three hundred and thirty-nine patients were included (58% men, median age at diagnosis of 70 years, Q1-Q3, 61-79): 33 pre-Sézary (9.7% of 339), 296 Sézary syndrome (87.3%), of whom 10 (2.9%) had large-cell transformation. One hundred and ten patients received mogamulizumab. Median follow-up was 58 months (95% confidence interval [CI], 53-68). OS was 46.5% (95% CI, 40.6%-53.3%) at 5 years. Multivariable analysis showed that age ≥ 80 versus <50 (HR: 4.9, 95% CI, 2.1-11.2, p = 0.001), and large-cell transformation (HR: 2.8, 95% CI, 1.6-5.1, p = 0.001) were independent and significant factors associated with reduced OS. Mogamulizumab treatment was significantly associated with decreased mortality (HR: 0.34, 95% CI, 0.15-0.80, p = 0.013).
INTERPRETATION
Treatment with mogamulizumab was significantly and independently associated with decreased mortality in Sézary syndrome.
FUNDING
French Society of Dermatology, Swiss National Science Foundation (IZLIZ3_200253/1) and SKINTEGRITY.CH collaborative research program.
File(s)
| File | File Type | Format | Size | License | Publisher/Copright statement | Content | |
|---|---|---|---|---|---|---|---|
| 1-s2.0-S258953702400258X-main.pdf | text | Adobe PDF | 495.2 KB | published |